Trial Profile

Phase 2, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Dose Escalation and Proof-of-Concept Study to Evaluate the Safety and Efficacy of Razuprotafib in Hospitalized Subjects With Coronavirus Disease 2019

Status: Discontinued

Phase of Trial: Phase II

Latest Information Update: 12 Jun 2023

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Razuprotafib (Primary)
Indications Adult respiratory distress syndrome; COVID-19 respiratory infection; Respiratory insufficiency; SARS-CoV-2 acute respiratory disease
Focus Proof of concept; Therapeutic Use
Acronyms RESCUE
Sponsors Aerpio Pharmaceuticals; EyePoint Pharmaceuticals

06 Jun 2023 Sequential has been added in design term as Intervention model.
17 May 2021 Results published (n=31) in the Aerpio Pharmaceuticals Media Release.
17 May 2021 According to an Aerpio Pharmaceuticals media release, this trial is sponsored by the Medical Technology Enterprise Organization (MTEC).

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com